RegeneRx Biopharmaceuticals, Inc. (OTCBB:RGRX) announced that it will be making a company presentation on October 23rd at the 4th Annual Techvest Healthcare Conference being held on October 22-24, 2002 in Boston, Massachusetts. The conference features biomedical and biopharmaceutical companies developing products for tissue repair, replacement and regeneration. Attendees will include major pharmaceutical companies and members of the venture capital and investment banking communities. J.J. Finkelstein, RegeneRx's President and CEO will be discussing the company's technology platform and the initiation of human clinical trials with thymosin beta 4 (Tß4) later this year.

Tß4 is a naturally occurring 43 amino acid peptide and the major actin-sequestering molecule in mammalian cells. As such, it plays a vital role in the regeneration, remodeling, and healing of injured or damaged tissues. Tß4 is found in highest concentration in blood platelets, the first molecules to reach the site of a wound. Tß4 has also been shown to influence T-cell differentiation, decrease toxicity induced by endotoxin and chemotherapy, and down-regulate a number of key inflammatory cytokines and chemokines. Tß4 has a significantly different mechanism of action than growth factors and may be delivered topically, virtually eliminating toxicity while allowing easy accessibility for frequent treatment. Numerous recent papers have been published in major scientific journals describing the results of research on Tß4 conducted at the National Institutes of Health (NIH) and other institutions.

RegeneRx Biopharmaceuticals, Inc., Bethesda, MD, (www.RegeneRx.com) holds an exclusive worldwide license for Tß4 from NIH for wound healing and is developing it for the treatment of a variety of human diseases. The Company holds several patents related to the technology and has numerous patent applications pending. RegeneRx expects to initiate human clinical trials for chronic dermal wounds by the end of this year. Earlier this year, the Company completed a $1.7 million equity investment round that included investment by a major private European pharmaceutical group.

The information in this press release may include certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements concern the Company's current expectations regarding future events, including the ongoing and prospective development and commercialization of Tß4 and possible future benefits to the Company, its shareholders, and patients. Due to the nature of product development and the regulatory approval process, the forward-looking statements contained in this press release are subject to risks and uncertainties, including those reflected in the Company's filings with the Securities and Exchange Commission, particularly its most recent Annual Report on Form 10-KSB. The Company assumes no obligation to update or revise any forward-looking statements made herein or any other forward-looking statements made by the Company.

Back To 2002 Press Release Archives